In vivo studies are designed to evaluate the antitumor efficacy of AAV‐mediated gene therapy and we show that targeting CAND1 has a therapeutic effect on HCC in cell line‐derived and patient‐derived xenograft (CDX and PDX) models. The gene discussed is CAND1; the disease is hepatocellular carcinoma.